ライフサイエンスコーパス: shRNA

1 shRNA knockdown of CD82 in myogenic cells reduces myobla

2 shRNA knockdown of the MYC -428 and -525 ESE eRNA caused

3 shRNA lentiviral plasmid vectors pLSLP-HK1, pLSLP-HK2, a

4 shRNA or small-molecule inhibition of PU.1 in AML cells

5 shRNA-mediated depletion of Actalpha reduces axonal filo

6 shRNA-mediated depletion of DOT1L reduced mRNA and prote

7 shRNA-mediated depletion of Kdm5b in proliferating adult

8 shRNA-mediated down-regulation of MITF in melanoma cells

9 shRNA-mediated inhibition of CXCL13 in the spinal cord p

10 shRNA-mediated knockdown of 14-3-3zeta in mpkCCD14 cells

11 shRNA-mediated knockdown of Cdc25A protects neurons in a

12 shRNA-mediated knockdown of isoform 2 in BRAFi resistant

13 shRNA-mediated partial knockdown of SSRP1 reduces HIV-1

14 shRNAs directed against each of these six genes down-reg

15 Analysis of signatures for over 13,000 shRNAs applied in 9 cell lines revealed that microRNA (m

16 2 silencing, we screened a library of 60,000 shRNAs using a cell line with a MeCP2 reporter on the Xi

17 HIF-1alpha shRNA blocked albumin-induced changes in these EMT marke

18 ing lentiviral vectors containing Hif-1alpha shRNA resulted in reduced expression levels of Vegf, Glu

19 collagen-I, which were blocked by HIF-1alpha shRNA.

20 An unbiased shRNA screen (7,500 genes and 20 shRNAs/genes) across 11 cell lines in the presence of a

21 essed for 7,837 genes using an average of 20 shRNAs per gene in 398 cancer cell lines.

22 Using Thbs4(-/-) mice and TSP-4 shRNA, we found that TSP-4 mediated pro-angiogenic funct

23 We tested 432 shRNAs specific for 144 selected genes for effects on Fc

24 By testing 4666 shRNAs derived from the CD95 and CD95L mRNA sequences an

25 Here, by conducting a shRNA screen targeting the kinome, we identified PIM1, a

26 on of the reprogramming plasmid containing a shRNA against TP53.

27 using adenovirus-mediated transfection of a shRNA into the third ventricle, transducing ependymal wa

28 Neurons electroporated with a shRNA targeting IGF-1 receptor failed to migrate to the

29 Finally, AAV-shRNA-mediated knockdown of VTA GLP-1 receptors was suff

30 Accordingly, shRNA-mediated suppression of Atg5, an E3 ubiquitin liga

31 observed by short hairpin ribonucleic acid (shRNA)-mediated MELK knockdown in cellular models.

32 rge over a more alkalized range of activity; shRNA-mediated depletion of Nalcn hyperpolarized RTN neu

33 S-susceptible genetic background that allows shRNA-mediated targeting of candidate genes in the adult

34 e performed sequencing-based screening of an shRNA library on a panel of cancer cells of different or

35 generation, we locally delivered XBP1s or an shRNA targeting this transcription factor to sensory neu

36 anism for trans-enhancement, we performed an shRNA screen of several hundred genes involved in organe

37 egulators relevant to cancer, we screened an shRNA library targeting genes deleted in hepatocellular

38 Through an shRNA screen, we identified the protein arginine methylt

39 ong with CRISPR-mediated gene activation and shRNA knockdown of DYRK1A, we show here that chemical in

40 Chromatin analysis and shRNA-mediated gene suppression experiments indicated a

41 ells attenuated TRAIL-induced apoptosis, and shRNA-mediated HOTAIR knockdown in TRAIL-resistant PANC-

42 cyte marker genes in the cultured cells, and shRNA knockdown of PPFP eliminated this pioglitazone eff

43 CpG and shRNA in iDR-NCs synergistically activate APCs for susta

44 e transcription, (2) self-assembling CpG and shRNA into DNA-RNA microflowers, (3) shrinking microflow

45 ere prepared by (1) producing tandem CpG and shRNA via concurrent rolling circle replication and roll

46 By combining genetic and shRNA depletion strategies, we define not only a dominan

47 Over 80% of multiple-tested siRNAs and shRNAs targeting CD95 or CD95 ligand (CD95L) induce a fo

48 AR shRNA or Enzalutamide inhibited the growth of SKBR3 cell

49 oach for the analysis of proliferation-based shRNA selection strategies and identifies new targets fo

50 Co-administration of TGF-beta shRNA and HBV dual-shRNA decreased HBV DNA, HBV RNA, HBs

51 onal culture, and inhibition of caspase-1 by shRNA or a specific chemical inhibitor improved the surv

52 Stable knockdown of ACTN4 by shRNA in HPCs significantly reduces dexamethasone-mediat

53 Knockdown of AhR by shRNA decreased BCRP expression, and this decrease was r

54 Depletion of BRD4 by shRNA and inhibition by (+)-JQ1, an inhibitor of BET fam

55 The knockdown of CAPS by shRNA eliminated the VAMP-2-dependent docking and evoked

56 that genetic silencing of the CcO complex by shRNA expression and loss of CcO activity in multiple ce

57 of mitochondrial calcium release, either by shRNA-mediated VDAC1 silencing or pharmacological inhibi

58 Inhibition of NRP1 expression by shRNA in both pancreatic and lung cancer cells containin

59 Inhibition of GAP-43 expression by shRNA significantly reduced seizure duration and severit

60 Knockdown of EZH2 by shRNA or siRNA resulted in inhibition of cell growth and

61 lls after loss of function of linc-GALMD3 by shRNA, we found that linc-GALMD3 could positively cis-re

62 onstrated that knockdown of GGA1 and GGA2 by shRNA and siRNA significantly reduced the cell surface e

63 Depletion of HDAC5 by shRNA hindered cellular proliferation, induced G1 cell c

64 hat silencing of Egr-1 in the hippocampus by shRNA reduces tau phosphorylation, lowers amyloid-beta (

65 ession of BIRC5 and/or IFI6 was inhibited by shRNA, the infected cells underwent apoptosis rather tha

66 CSE1L knockdown by shRNA inhibited protein, resulting in decreased cell pro

67 te outgrowth, an effect that was mimicked by shRNA targeting the N1-Src microexon.

68 Downregulation of the mitofusins by shRNA to ~45% or ~52% of the control levels attenuated t

69 letion of JB12 during reductive stress or by shRNA from Huh-7 cells was associated with accumulation

70 ication, either by an ACAT-1 inhibitor or by shRNA knockdown, significantly suppressed tumor growth a

71 LF as a substrate for ABCA3 was performed by shRNA gene knockdown (KD) in THP-1 monocytes.

72 Down-regulation of PKM2 by shRNA blunts cellular responses to shikonin but enhances

73 Targeted depletion of PPM1A by shRNA or inhibition of PPM1A activity by sanguinarine re

74 rthermore, when dorsal CA1 Ih was reduced by shRNA-HCN1, the CUS-induced behavioral deficits were pre

75 hibitory role for TRAIL-R3/4 was revealed by shRNA knockdown and mAb blockade, showing that these reg

76 eover, blocking the PTN-PTPRZ1 signalling by shRNA or anti-PTPRZ1 antibody potently suppressed GBM tu

77 I (NDUFV1) and complex II (SDHC) subunits by shRNA in B16rho(0) cells abolished or significantly reta

78 Gs recorded after mice Kir7.1 suppression by shRNA, or by blocking with VU590, showed reduced a-, b-

79 Vector carrying shRNA against TGF-beta, though did not inhibit HBV repli

80 Genetic (CD44v6 shRNA) or a small molecule inhibitor (CD44v6 peptide) ta

81 Here, we develop a compact shRNA (cshRNA) expression system based on retroviral mic

82 es and facilitates the generation of compact shRNA libraries.

83 r Insr or Irs1/2 was achieved by conditional shRNA expression, severely attenuating insulin-stimulate

84 , Glut1, Pgk1, and Col10 compared to control shRNA.

85 ptor (EGFR) dependency by performing CRISPR, shRNA, and expression screens in a non-small cell lung c

86 We used lentiviral-delivered shRNA or siRNA to inhibit PLVAP expression.

87 r RUNX3 or CBFbeta with lentivirus-delivered shRNA impaired epitope-tagged EBNA3B and EBNA3C binding

88 Interestingly, two different shRNA screens failed to identify a single TP53 target ge

89 ginine-creatine metabolism by CKMT1-directed shRNAs or by the small molecule cyclocreatine selectivel

90 tably expressing doxycycline-inducible DOT1L shRNA, ablating DOT1L expression with doxycycline signif

91 oters (U6 or H1) are typically used to drive shRNA expression.

92 tions, the robust expression of U6/H1-driven shRNAs can induce toxicity and generate heterogeneous sm

93 dministration of TGF-beta shRNA and HBV dual-shRNA decreased HBV DNA, HBV RNA, HBsAg, HBeAg, and live

94 combination of two short hairpin RNAs (dual-shRNA) against different coding regions of HBV delivered

95 The dual-shRNA also exhibited stronger antifibrotic activity in v

96 hms and reliably predicts the most efficient shRNAs for a given gene.

97 By use of a adenoviral eIF5A shRNA, we have achieved an effective depletion of eIF5A

98 proteome of HeLa cells transduced with eIF5A shRNA was compared with that of scramble shRNA-transduce

99 Silencing of XPO1 by either shRNA or selinexor significantly reduced cellular growth

100 ed that hepatotoxicity arises when exogenous shRNAs exceed 12% of the total amount of liver microRNAs

101 ected with adeno-associated virus expressing shRNA against Cldn5 caused infiltration of the periphera

102 no-associated virus (rAAV) vector expressing shRNAs (rAAV-shRNAs); however the mechanism by which tox

103 ) proximal tubules and Slc27a2(-/-) or FATP2 shRNA-treated proximal tubule cell lines compared with w

104 ulating senescence, we carried out a focused shRNA screen.

105 This focused shRNA library was infected into cells followed by analys

106 system reduces the coding space required for shRNA expression by >2-fold as compared to the typical U

107 base pairs (bp) of vector space required for shRNA expression.

108 MSI2-interacting RBP network and functional shRNA screening, we identified 24 genes required for in

109 Furthermore, shRNA knockdown of Cav-1 expression decreased nucleotide

110 Furthermore, shRNA-mediated silencing of USP14 or UCHL5 in Ewing sarc

111 We identify PRMT5 in an in vivo GBM shRNA screen and show that PRMT5 knockdown or inhibition

112 particularly when delivery of multiple gene/shRNA combinations is required.

113 A forward genetic shRNA library screen revealed Hoxa1 as a critical mediat

114 Here, using a human whole-genome shRNA library, we identify TMIGD3 isoform1 (i1) as a fac

115 rted, RNAi-mediated silencing in a HepG2/GFP-shRNA RNAi sensor line.

116 DZ dominant-negative mutant or possibly GODZ shRNA, should be considered a potential alternative ther

117 tifibrotic activities of single and dual HBV shRNAs.

118 embly and secretion was inhibited by hepatic shRNA-induced apoB silencing or genetic or pharmacologic

119 stabilization accelerated, whereas HIF1alpha shRNA delayed wound closure.

120 he BLA with stereotaxic injection of 5-HT2CR shRNA AAV vector decreased vocalizations and anxiety- an

121 hole-genome transcription analysis of ICBP90 shRNA-treated rheumatoid synoviocytes uncovered a subset

122 in DCM from PELP1-cyto HMECs expressing IKK shRNA.

123 Finally, targeted IL8 shRNA inhibited BM-MSC-induced AML survival.

124 upported by their agreement with independent shRNA essentiality profiles and homozygous gene deletion

125 RAGE knockdown with multiple independent shRNAs in breast cancer cells led to decreased transwell

126 val of murine PDAC cells, using an inducible shRNA-based system that enables temporal control of Kras

127 PREX1 overexpression increased but its shRNA knockdown decreased ERK1/2 phosphorylation in resp

128 staurosporine-induced apoptosis whereas its shRNA knockdown promoted apoptosis in response to stauro

129 ion of a CXCR7 agonist or PCEC-targeted Jag1 shRNA after lung injury promotes alveolar repair and red

130 SP600125) or knockdown technology (Lenti-JNK-shRNAs) resulted in significantly suppressed cyst breakd

131 Lentiviral shRNA-mediated knockdown (KD) of PKCiota leads to decrea

132 NF-kappaB signaling pathways, and lentiviral shRNA or inhibitor of TRPC3 channels may become novel an

133 Following lentiviral shRNA knockdown in several human liver cancer cell lines

134 cose 6-dehydrogenase (UGDH) using lentiviral shRNA effectively decreased HA production but did not af

135 a-catenin activity in vivo, where lentiviral shRNA depletion of Ror2 expression augmented canonical W

136 ranasal delivery of TRPC3 channel lentiviral shRNAs or blocker 1-[4-[(2,3,3-trichloro-1-oxo-2-propen-

137 he specific ablation of bpoz-2 by lentiviral-shRNA stimulates the load of monomeric and polymeric for

138 that overlapped with those regulated by MIF shRNA.

139 Xenografts expressing MIF-shRNA grew more rapidly with greater angiogenesis and ha

140 Moreover, shRNA knockdown of PP5 results in cells refractory to ro

141 he interpretation of the effects of multiple shRNAs over multiple cell line passages.

142 c18c(+/-)) and human pancreas (lenti-Munc18c-shRNA-treated) exhibit normal apical exocytosis of zymog

143 rmore, MYST3 inhibition with inducible MYST3 shRNAs potently attenuated breast tumor growth in mice.

144 phosphate transport were abolished by NHERF1 shRNA knockdown.

145 We found that NRP1 shRNA expressing KRAS (mt) tumor cells caused increased

146 WT neurons, thereby mimicking conditions of shRNA-transfected neurons previously used to characteriz

147 Our results suggest that the combination of shRNAs against HBV and TGF-beta could be developed into

148 PP knock-down by in utero electroporation of shRNAs with whole-cell electrophysiology.

149 Mice with inducible expression of shRNAs against Anln mRNA developed fewer liver tumors af

150 Here, we found that using optimized shRNAs embedded within an miRNA (shRNAmiR) architecture

151 TF blockade by antibody or shRNA diminished the procoagulant activity of EMT-positi

152 HSV) vector expressing either CRISPR/Cas9 or shRNA targeted against Fto.

153 expression via CRISPR-Cas9 gene deletion or shRNA knockdown had no effect on the efficacy of ADCs wi

154 Conversely, genetic or shRNA-mediated conditional KO/knockdown of GSK3beta redu

155 F138 function with a mutant (RNF138-H36E) or shRNA infection significantly upregulates the CaV2.1 pro

156 Pharmacologic inhibition or shRNA knockdown of ILK prevented periostin-induced Akt/m

157 nasteride upon pharmacological inhibition or shRNA-mediated ablation of COX-2.

158 lization in the presence of CK2 inhibitor or shRNA targeting CK2alpha.

159 ation of its expression by overexpression or shRNA knockdown alters axon branching in cultured DRG ne

160 the renalase monoclonal antibody m28-RNLS or shRNA knockdown of renalase inhibited pancreatic ductal

161 mmunostimulatory and cytotoxic capacity of p-shRNA make it an attractive platform for cancer immunoth

162 an conventional dsRNA, the cytotoxicity of p-shRNA was either equal to or substantially greater than

163 The cytotoxicity of p-shRNA was robustly observed across four different cancer

164 le transcription fold into periodic-shRNA (p-shRNA) structures and cause potent cytotoxicity and gene

165 the dumbbell templates used to synthesize p-shRNA, and showed that these molecules likely adopt a co

166 ling circle transcription fold into periodic-shRNA (p-shRNA) structures and cause potent cytotoxicity

167 ntly from PLCgamma2, we found that PLCgamma1 shRNA significantly suppresses OC differentiation by lim

168 Our findings also suggest that pooled shRNA libraries could be valuable tools for genome-wide

169 Here, through pooled shRNA screening of colorectal cancer cells, we identifie

170 and stable re-expression of PAX2 in MOE:PTEN(shRNA) cells significantly reduced proliferation and per

171 Phosphatase and tensin homolog (PTEN)(shRNA) negatively regulated PAX2 expression and stable r

172 virus (rAAV) vector expressing shRNAs (rAAV-shRNAs); however the mechanism by which toxicity ensues

173 Using rAAV-shRNAs we have now determined that hepatotoxicity arises

174 Toll-like receptor (TLR) 2 or TLR4, and RAGE shRNA inhibited HMGB1-induced EMT in human airway epithe

175 In vivo, targeting RAGE shRNA knockdown in human and mouse breast cancer cells,

176 Using retroviral shRNA knockdown, we have demonstrated that these JAK inh

177 We performed whole-genome small hairpin RNA (shRNA) "dropout screens" on 77 breast cancer cell lines.

178 d synergistic DNA CpG and short hairpin RNA (shRNA) adjuvants, as well as tumor-specific peptide neoa

179 s were inhibited by STIM1 short hairpin RNA (shRNA) and absent in TRPC1(-/-) cells, and store-operate

180 e compared the ability of short hairpin RNA (shRNA) and CRISPR/Cas9 screens to identify essential gen

181 In parallel, 362 short-hairpin RNA (shRNA) constructs against 276 unique RBPs were also used

182 ts using lentivirus-based short hairpin RNA (shRNA) delivery.

183 We show that short hairpin RNA (shRNA) depletion of TET2 results in a decrease in latenc

184 ere transfected with DBR1 short hairpin RNA (shRNA) followed 48 h later by infection with an HIV-1-de

185 t depletion of EYA1 using short hairpin RNA (shRNA) in breast cancer cells destabilizes the Myc prote

186 o electroporation of NDE1 short hairpin RNA (shRNA) in embryonic rat brains, we observe cell cycle ar

187 TIM1 antibodies and STIM1 short hairpin RNA (shRNA) in wild-type VSMCs, and was absent in TRPC1(-/-)

188 ain kinase 1 (LIMK1) with short hairpin RNA (shRNA) inhibits HIV infection, no specific small-molecul

189 ecoy receptor B18R nor by short hairpin RNA (shRNA) knockdown of mitochondrial antiviral signaling pr

190 of TACC3 from cells using small hairpin RNA (shRNA) knockdown or small-molecule targeting reduced mit

191 -MEL-28) cell lines using short hairpin RNA (shRNA) lentiviral vectors.

192 ing mutant Krt75-specific short hairpin RNA (shRNA) persistently suppressed this phenotype.

193 Through a short hairpin RNA (shRNA) screening, we identified single-stranded DNA bind

194 enous NFAT3 expression by short hairpin RNA (shRNA) significantly inhibited tumor cell proliferation,

195 ers and cognate-inducible short hairpin RNA (shRNA) targeted against the reporter coding region, we h

196 Knockdown of Hrs by short hairpin RNA (shRNA) transduction resulted in significant decreases in

197 been depleted of Rab1B by short hairpin RNA (shRNA) treatment, indicating that T2S also potentiates e

198 lines using DDX3-specific small hairpin RNA (shRNA), and assessed oncogenic activity.

199 pathway was inhibited by short hairpin RNA (shRNA), HBoV1-induced cell death dropped significantly;

200 Using small hairpin RNA (shRNA), which was validated in cultured neuronal cells,

201 Short hairpin RNA (shRNA)-mediated knockdown of LC3 prevented AML cell deat

202 We demonstrate that short hairpin RNA (shRNA)-mediated knockdown of Megf10, as well as overexpr

203 Indeed, short-hairpin RNA (shRNA)-mediated knockdown of p62 impaired breast cancer

204 69(-/-) reporter mice and short hairpin RNA (shRNA)-mediated silencing and miR-155 transfection appro

205 Using short hairpin RNA (shRNA)-mediated suppression of NRP1, we demonstrate that

206 avin depletion and Gravin short hairpin RNA (shRNA)-treated cells, an increase in cells containing mi

207 Ai-based methods such as short-hairpin RNAs (shRNA).

208 n of transgenes encoding small hairpin RNAs (shRNAs) against Anln messenger RNA and studied liver tum

209 n of all six genes using short hairpin RNAs (shRNAs) and follow-up functional studies demonstrated th

210 Short hairpin RNAs (shRNAs) are effective in generating stable repression of

211 B, DDB1 or DCAF11, using short hairpin RNAs (shRNAs) attenuated the ubiquitination level of p21(Cip1)

212 as engineered to produce short hairpin RNAs (shRNAs) corresponding to the Aedes aegypti orthologs of

213 A screen using pooled short hairpin RNAs (shRNAs) identified the ATP-buffering, mitochondrial crea

214 ss of RNAi therapeutics, small hairpin RNAs (shRNAs) must co-opt sufficient quantities of the endogen

215 ession or knockdown with short hairpin RNAs (shRNAs).

216 nsequences of expressing short hairpin RNAs (shRNAs).

217 ct potent microRNA-based short hairpin RNAs (shRNAs).

218 RPL4 shRNA knockdown decreased EBNA1 activation of an oriP lu

219 PI3K inhibition by conducting a genome scale shRNA-based apoptosis screen in a PIK3CA mutant human br

220 We used a genome-scale shRNA viability screen in human cancer cell lines to sys

221 F5A shRNA was compared with that of scramble shRNA-transduced counterpart by the iTRAQ method.

222 pes of ovarian cancer cells expressing SHMT1 shRNAs.

223 We now show these si/shRNAs kill cancer cells through canonical RNAi by targe

224 preadipocytes stably transfected with Siah2 shRNA and that overexpression of Siah2 in non-precursor

225 Significantly, shRNA-mediated knockdown of hG9a attenuated p53-dependen

226 mygdala, using a lentivirus with a silencing shRNA (small hairpin RNA targeting A2AR (shA2AR)), impai

227 showed better antiviral effects than single shRNA both in vitro and in HBV-persistent mice.

228 2 cell-derived xenografts expressing SLC13A5-shRNA in nude mice.

229 strate that knockdown of Kv3.4 by a specific shRNA impedes axon initiation, elongation, pathfinding,

230 down of TRPC6 in kidney using TRPC6 specific shRNA construct significantly attenuated Ang II-induced

231 firmed by stable expression of gene-specific shRNAs in hCSCs.

232 Here, we utilized PLCgamma1-specific shRNAs to delete PLCgamma1 in OC precursors derived from

233 , we used lentiviral delivery of human Spry1 shRNAs to suppress Spry1 expression in MDA-MB-231, an es

234 b in FLT3-ITD(+) AML cells expressing stable shRNA against endogenous Drp1.

235 We have discovered using stable shRNA gene suppression that GnT-III expression controls

236 sensor GFP-PLCdelta1-PH was reduced by STIM1 shRNA and absent in TRPC1(-/-) cells.

237 sphorylation of TRPC1 was inhibited by STIM1 shRNA.

238 In this study, shRNA silencing of PDIA6 expression in insulin-producing

239 After this threshold was surpassed, shRNAs specifically reduced the initially synthesized 22

240 ressing tetracycline-inducible AREG-targeted shRNA with lentiviruses expressing silencing-proof, memb

241 d, intracardiac injection of Gbeta5-targeted shRNA allowed for heart-specific protection against the

242 that inducible expression of a UBC-targeting shRNA led to tumor regression, and substantial long-term

243 mutant of ULK1 or ATG4b or a ULK1-targeting shRNA facilitated cell migration in vitro Functional pro

244 eraction biochemically and demonstrated that shRNA knockdown of PACSIN1 in hippocampal neurons increa

245 schemic insult in vivo Finally, we show that shRNA targeting Cdc25A blocks Ser795 pRb phosphorylation

246 Here we show that shRNA-mediated depletion of the m(6)A-forming enzyme MET

247 We have previously shown that shRNA-mediated silencing of one of these ligands, amphir

248 The shRNA library was designed to target a subset of genes p

249 e regardless of the level or sequence of the shRNA.

250 gle-cell RNA sequencing (scRNA-seq) with the shRNA screen to investigate the mechanism of action of t

251 Finally, cells electroporated with the shRNA targeting IGF-1 receptor were unable to form an ax

252 analysis of enrichment and depletion of the shRNAs over the course of cell proliferation.

253 ve for knockdown, however, compared to their shRNA counterparts.

254 This was validated through shRNA-mediated knockdown of the target protein, HNF1beta

255 grafted mice with viral vector-delivered TLX shRNA or nanovector-delivered TLX siRNA inhibits tumour

256 eloid leukemia cell line K562 in response to shRNA knockdown of the RNA editing enzyme ADAR1.

257 axin 7 with silencing efficacy comparable to shRNAs, and introduce silent mutations into an ataxin 7

258 Dok-7 expression was reduced by transfecting shRNA-coding plasmids into the tibialis anterior muscle

259 ective effects were observed after transient shRNA-mediated silencing of Rps19, but not several other

260 enome-wide screen with a pooled ultracomplex shRNA library and in vitro system modeling HIV latency a

261 An unbiased shRNA screen (7,500 genes and 20 shRNAs/genes) across 11

262 Using an unbiased shRNA screen targeting known kinases, we identified brom

263 C2-null lung tumors, and introduction of uPA shRNA in tumor cells or amiloride-induced uPA inhibition

264 icient MECs were able to form organoids upon shRNA-mediated c-Src knockdown.

265 t NOX1 plays in colon cancer growth, we used shRNA to decrease NOX1 expression stably in HT-29 human

266 Using shRNA silencing and ectopic expression of HLJ1, we found

267 Using shRNA targeting CTCF to recapitulate CTCF haploinsuffici

268 tagonists or genetic targeting of A2AR using shRNA.

269 were increased upon depletion of ASK1 using shRNA in MLE-12 cells, but unaffected when PP5 was deple

270 ased when PP5 expression was decreased using shRNA, but migration was increased in ATII cells isolate

271 ctive reduction of Ephexin5 expression using shRNA in the dentate gyrus of presymptomatic adolescent

272 pressed in GSCs and knockdown of KDM1A using shRNA-reduced GSCs stemness and induced the differentiat

273 in select brain regions of adult mice using shRNAs.

274 t inhibition of the expression of alphaB via shRNA inhibits exosome secretion from ARPE19 cells indic

275 at can be suppressed by targeting MUC1-C via shRNA silencing, CRISPR editing, or pharmacologic inhibi

276 TRX1 inhibition via shRNA or a phase I-approved inhibitor, PX-12 (untested i

277 In vivo TRX1 inhibition via shRNA or PX-12 reverses the castration-resistant phenoty

278 uppel-like transcription factor 9 (KLF9) via shRNA promotes long-distance axon regeneration after opt

279 c inhibitor saracatinib or its knockdown via shRNA dramatically altered adhesion and spreading of fre

280 Conversely, acute suppression of RNF145 via shRNA-mediated knockdown, or chronic inactivation of RNF

281 ubiquitylate the water channel AQP2 in vitro shRNA knockdown of CHIP in CCD cells increased AQP2 prot

282 *NONO and XLF function redundantly in vitro, shRNA-mediated knockdown experiments indicate that NONO

283 In vivo shRNA knockdown of Ptprb in the cleared mammary fat pad

284 Using a combined pooled-genome wide shRNA library screen and global proteomic profiling, we

285 Functional genomic data from a genome-wide shRNA screen in Ewing sarcoma cells also identified the

286 Using a genome-wide shRNA screen in human FA fibroblasts, we identify transf

287 duced senescence, we performed a genome-wide shRNA screen in primary human fibroblasts expressing OSK

288 Here, in a genome-wide shRNA-based screen, we identified nuclear export factor

289 IKBKE ablation with shRNA or small-molecule inhibitor amlexanox selectively

290 H2.35 liver cells with shRNA knockdown of ANLN formed tumors more slowly in FRG

291 Live cell imaging in concert with shRNA tau knockdown revealed that reducing tau expressio

292 After Ano5 gene knock-down with shRNA in MC3T3-E1 osteoblast precursors we saw elevated

293 rs was also affected by electroporation with shRNA targeting IGF-1 receptor.

294 hemical inhibition or genetic knockdown with shRNA abated aSyn truncation.

295 population, we transplanted >1,300 mice with shRNA-transduced HSPCs within 24 h of isolation and tran

296 , by combining Notch ligand microarrays with shRNA-based knockdown of Notch ligands, we systematicall

297 Silencing PRMT5 with shRNA or blocking PRMT5 methyltransferase activity with

298 urial macrophages, or inhibition of RET with shRNA or a small-molecule inhibitor, reduced perineurial

299 Co-transfection with shRNA vectors against HK1, HK2, and HK3 mRNAs resulted i

300 Knockdown of AR with shRNAs and a new generation anti-androgen drug, Enzaluta